Catalina Villota-Eraso

Catalina Villota-Eraso

Auto-generated profile, based on publicly available information

Catalina Villota-Eraso

Department of Rheumatology, Universidad de la Sabana, Chia, Colombia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in The Lancet Rheumatology
Verified
Journal Article
Closed access
LGLeticia Garcia-Montoya
Leticia Garcia-Montoya
CVCatalina Villota-Eraso
Catalina Villota-Eraso
MYMd Yuzaiful Md Yusof
Md Yuzaiful Md Yusof
EVEdward M Vital
Edward M Vital
PEPaul Emery
Paul Emery

20 September 2022 in La radiologia medica
Verified
Journal Article
Open access
PDF file
FSFausto Salaffi
Fausto Salaffi
MCMarina Carotti
Marina Carotti
AMAndrea Di Matteo
Andrea Di Matteo
LCLuca Ceccarelli
Luca Ceccarelli
SFSonia Farah
Sonia Farah
AGAndrea Giovagnoni
Andrea Giovagnoni
Sarcopenia is characterized by loss of muscle mass, altered muscle composition, fat and fibrous tissue infiltration, and abnormal innervation, especially in older individuals with immune-mediated rheumatic diseases (IMRDs). Several techniques for measuring muscle mass, strength, and performance have emerged in recent decades. The portable dynamometer and gait speed represent the most frequently used tools for the evaluation of muscle strength and physical efficiency, respectively. Aside from dual-energy, X-ray, absorptiometry, and bioelectrical impedance analysis, ultrasound (US) and magnetic resonance imaging (MRI) techniques appear to have a potential role in evaluating muscle mass and composition. US and MRI have been shown to accurately identify sarcopenic biomarkers such as inflammation (edema), fatty infiltration (myosteatosis), alterations in muscle fibers, and muscular atrophy in patients with IMRDs. US is a low-cost, easy-to-use, and safe imaging method for assessing muscle mass, quality, architecture, and biomechanical function. This review summarizes the evidence for using US and MRI to assess sarcopenia.

20 June 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
DFDaniel G. Fernández-Ávila
Daniel G. Fernández-Ávila
JRJulián Rondón-Carvajal
Julián Rondón-Carvajal
CVCatalina Villota-Eraso
Catalina Villota-Eraso
JGJuan Martín Gutiérrez-Dávila
Juan Martín Gutiérrez-Dávila
KCKateir Mariel Contreras-Villamizar
Kateir Mariel Contreras-Villamizar

20 February 2018 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
Yimy F. MedinaYimy F. Medina
Yimy F. Medina
RRRafael Eduardo Ruíz-Gaviria
Rafael Eduardo Ruíz-Gaviria
ABAdriana Buitrago-Lopez
Adriana Buitrago-Lopez
CVCatalina Villota
Catalina Villota

1 June 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
CVC. Villota
C. Villota
ORO. Roa
O. Roa
MDM. Díaz
M. Díaz
JGJ. Gutiérrez
J. Gutiérrez
DFD.G. Fernández-Avila
D.G. Fernández-Avila
Background The Human Leukocyte Antigen HLA B 27; is a class I antigen from MHC that is strongly associated with ankylosing spondylitis (AS) and other spondyloarthritis (SPA), with positivities for HLA-B27 in the population from 80 to 95% worldwide. The prevalence of HLA-B27 in the general population varies by geographic area, with ratios ranging between 2-4% in African/African American compared to 8% in Caucasian populations 1 Objectives To determine the proportion of positive HLA B 27 in the population of transplanted and donors treated at the San Ignacio University Hospital; their clinical characteristics and relationship to the presence of spondyloarthritis. Methods It was performed a descriptive cross-sectional study of 465 individuals typed for HLA of a cohort of transplants in a university hospital in Colombia including donors and receivers. Designing a database in Excel to include data relevant to the study. The search was performed in hospital records and telephone contact for family not treated at the hospital to extract information. Results 465 individuals with an age range between 10 and 80 years with a mean of 44.9 years (SD: 14.04); finding 21 positive cases for HLA B 27 indicating a prevalence of 4.5% positivity for HLA-B27 in this population. At evaluating the behavior by gender, a proportion of HLA B 27 of 6,5% was found in the group of men (n=261; 56.1%) compared with 2.0% in women. Of the 21 patients positive for HLA B 27 it was found that 4 of them (19%) had joint pain of small and large joints so they were referred to evaluation by the Rheumatology service at Hospital where the presence of spondyloarthritis or other autoinmune disease was discarted. Proportion of HLA B 27 (+) in the population of renal and bone marrow transplanted and donors at San Ignacio Universitary Hospital Conclusions It has been described in the literature the prevalence of HLA B 27 in ranges from 2% to 8%, according to the region evaluated; it was found in our study a ratio of 4.5% of the total population and comparing by gender a higher proportion in males (6.5% compared with 2% in women). Spondylitis or other autoimmune disease were not detected in any patient of the series evaluated in our study; although 19% of the populatinon with positive HLA B 27 was referred to rheumatology for articular symptoms discarding the presence of it. San Ignacio Universitary Hospital is a reference center of the city to perform transplants, so it is important to emphasize the prevalence found in our study that fits within international parameters reported. Disclosure of Interest None declared

1 June 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JSJ.C. Sarmiento-Monroy
J.C. Sarmiento-Monroy
CVC. Villota-Eraso
C. Villota-Eraso
MMM.J. Mantilla-Ribero
M.J. Mantilla-Ribero
NMN. Molano-González
N. Molano-González
MRM. Rodríguez-Jiménez
M. Rodríguez-Jiménez
RMR.D. Mantilla
R.D. Mantilla
Background Therapeutic guidelines draw heavily on evidence from randomized controlled trials undertaken in well-characterized, highly-selective populations and managed in tightly-controlled settings. As such, the extent to which therapeutic efficacy in real-life populations and routine care settings is often unclear [1–2]. Objectives To assess subcutaneous (SC) abatacept (ABA) efficacy and safety in a real-life setting. Methods This was a retrospective and single center study in which 94 patients (1987 ACR) were assessed from April 2014 to January 2016. The patients were stratified according to their treatment background: (n=39) biologic-naïve, (n=22) switched from IV to SC ABA administration (125mg-wk), and (n=33) inadequate response to TNF inhibitor (TNF-IR). The primary and secondary endpoints were change in DAS28-CRP, and Routine Assessment of Patient Index Data (RAPID3) from baseline to 6 months, respectively. A linear mixed effects model was made to account for correlation among repeated measures. Adverse events (AEs) were assessed and recorded at each visit to the rheumatology center. Results Baseline characteristics of patients were as follows: female gender 86%, mean age 55.2±12.3 years, median disease duration 12.5 (IQR 14) years, Rheumatoid Factor positive 94%, Anti-Cyclic Citrullinated Peptide Antibodies 84%, mean DAS28-CRP 5.4±0.72, and mean RAPID3 15.6±5.0. SC ABA monotherapy, concomitant use of methotrexate (MTX), and leflunomide were reported in 10%, 48%, and 27%, respectively. Demographics and disease characteristics were similar in all groups, except for baseline DAS28-CRP (p<0.0001), and RAPID3 (p<0.0001) in switch group. After 6 months of administration, the DAS28-CRP score change was statistically significant irrespective of group. The scores changed from 5.4±0.9 to 3.8±1.3 (p<0.0001, biologic-naïve group), from 3.1±1.2 to 2.7±1.2 (p=0.002, switch IV-SC group), and from 4.6±1.9 to 3.2±1.4 (p=0.0305, TNF-IR group). The RAPID3 scores changed from 18.1±5.4 to 12.1±6.3 (p<0.0001, biologic-naïve group), from 10.4±6.6 to 9.2±7.0 (p=0.0114, switch IV-SC group), and from 16.1±5.7 to 11.8±7.1 (p=0.284, TNF-IR group). No patients relapsed or needed to return to the IV administration. Infections, headache, and constitutional symptoms, occurred in 48%, 37% and 32% of patients, respectively. Serious infections were reported only in 2% of patients (i.e., herpes zoster). Local injection-site reactions occurred in 13% of patients. Most of AEs reported were reversible and mild. There were no treatment discontinuations. No deaths and malignancies were reported. Conclusions Our results disclose an improvement in RA disease activity and physical function, during 6 months administration of SC ABA. Patients switching from IV to SC formulation of ABA had lower activity and functional impairment at baseline, and efficacy was maintained through follow-up. SC ABA demonstrated a good safety profile, consistent with previously published data. Reggia R, et al. J Rheumatol 2015;42(2):193–5. Nüβlein H, et al. Arthritis Rheum 2012;64(Suppl10):S199. Disclosure of Interest None declared